Hydrogel

Global Drug Delivery Devices Market Outlook to 2027 by Device Type, Route of Administration, Application, End-user, Vehicle Outlook, and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 13, 2021
Pharmaceutical, Health, Medical Devices, Diabetes, Autoimmune disease, Niosome, Administration, CAGR, Cancer, Growth, Stent, Hospital, Neurological disorder, Oral, USD, Geography, Midsayap Diagnostic Center and Hospital, Route of administration, Degenerative disease, Liposome, Bayer, Hydrogel, SCSI Peripheral Device Type, Application, Material, Drug recall, Pharmaceutical industry, Medical device

Additionally, the growth of biologics is significantly contributing to the drug delivery device market.

Key Points: 
  • Additionally, the growth of biologics is significantly contributing to the drug delivery device market.
  • However, factors such as drug recalls and biocompatibility issues with increased side effects are likely to restrain the market growth of drug delivery devices.
  • The Global Drug Delivery Devices Market is segmented based on device type, route of administration, application, end-user, vehicle outlook, and Geography.
  • By Device Type, the market is classified as smart pills, inhalers, drug-eluting stents, safety syringes, implantable drug delivery devices, transdermal patches, and others.

Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics

Retrieved on: 
Wednesday, September 22, 2021
Veterinary medicine, Temperature, Food, Neoplasm, OTCQB, Animal, Washington State University Reactor, Brachytherapy, Radiation, FDA Center for Devices and Radiological Health, Sale, Half-life, FDA, Certification, Washington, Food and Drug Administration, Structured Product Labeling, University, Company, Vivos, Missouri, Gel, Confusion, Sarcoma, Technology, Human, Tissue, Safety, Hydrogel, Name, GLOBE, Medical device, Medical imaging

Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training for new regional clinics.

Key Points: 
  • Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training for new regional clinics.
  • The modules are now on the FX Masse website with a separate unique UR web browser for Vivos Inc.
  • A new clinic can complete each module at their convenience as a pre-cursor to the hands-on certification training sessions.
  • We needed to create an efficient and consistent process to initiate the establishment of regional clinics for IsoPet therapy.

Vivos Inc. Files Early Feasibility IDE Application with FDA for Radiogel™

Retrieved on: 
Monday, September 20, 2021
Food, Temperature, Veterinary medicine, Neoplasm, OTCQB, Animal, Washington State University Reactor, Brachytherapy, Radiation, Food and Drug Administration, Review, Investigator's brochure, Efficiency, FDA Center for Devices and Radiological Health, Sale, Half-life, FDA, IDE, Washington, Structured Product Labeling, University, Company, Vivos, Communication, Missouri, Gel, Confusion, Sarcoma, Technology, Human, Tissue, Safety, Hydrogel, Name, GLOBE, Pharmaceutical industry, Medical imaging

The FDA recommended this path to facilitate enhanced ongoing communication with Vivos and to increase the efficiency of the review process.

Key Points: 
  • The FDA recommended this path to facilitate enhanced ongoing communication with Vivos and to increase the efficiency of the review process.
  • This filing is an important milestone for Vivos and reflects the efforts of numerous parties.
  • In particular, we are pleased that this IDE filing included the Mayo Clinic Clinical Trial Protocol for Radiogel, which is currently being reviewed by Mayos Independent Review Team.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).

DGAP-News: DEFENCE THERAPEUTICS FILES ACID-BASED HYDROGELS USA PROVISIONAL PATENT APPLICATION

Retrieved on: 
Tuesday, August 31, 2021
Industry, Company, CAGR, Gel, Solvent, USA, CSE, Infection, Therapy, Food, Cancer, Eastman Kodak Co. v. Image Technical Services, Inc., ADC, Engineering, Agriculture, Administration, Mining, Final good, Cosmetics, Catastrophic illness, Novartis, Cell, Forward-looking statement, Temperature, Vaccine, DGAP, Report, 3M, Hydrogel, Water, Control, News, Technology, Kinetics, Security (finance), Fine chemical

Vancouver, BC, Canada, August 31st, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines is pleased to announce the expansion of its patent portfolio through the filing of itsAccumTM technology-based USA Provisional Patent Application named "Steroid Acid-Based Hydrogels".

Key Points: 
  • Vancouver, BC, Canada, August 31st, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines is pleased to announce the expansion of its patent portfolio through the filing of itsAccumTM technology-based USA Provisional Patent Application named "Steroid Acid-Based Hydrogels".
  • Hydrogels are cross-linked polymer networks that can swell and retain a significant amount of water within its structure.
  • "The hydrogels sector is growing at a fast pace and Defence's versatility of its AccumTM technology gives Defence another business opportunity that the Defence team is planning to advance to a commercialization level.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.

Global Hydrogel-based Drug Delivery System Market Analysis Report 2021-2028: Polymer Origin (Natural, Synthetic, Hybrid), Route (Subcutaneous, Ocular, Oral Cavity) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021
Medical Devices, Medical Supplies, Infectious Diseases, Hospitals, Chemicals, Plastics, Manufacturing, Cardiology, Health, Pharmaceutical, Gel, Half-life, Hydrogel, Innovation, USD, Patient, Chemistry, Pain management, CAGR, Medicine, Chapter Three, Administration, Porosity, Subcutaneous, Research, Nature, Asia, Cardiology, Oral, Fine chemical, Pharmaceutical industry, Healthcare

The "Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report by Polymer Origin (Natural, Synthetic, Hybrid), by Route (Subcutaneous, Ocular, Oral Cavity), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report by Polymer Origin (Natural, Synthetic, Hybrid), by Route (Subcutaneous, Ocular, Oral Cavity), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global hydrogel-based drug delivery system market size is anticipated to reach USD 10.6 billion by 2028, expanding at a CAGR of 7.5%
    Surging demand for controlled release drug delivery systems across many therapeutic areas is a key factor expected to contribute to market growth during the forecast period.
  • Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner.
  • Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.

Hydrogel holds life-giving cells longer

Retrieved on: 
Friday, August 6, 2021
Gene, Cytokine, Cell, Safety, Advanced Materials, B cell, Vaccine, Mouse, Moyamoya disease, Technology, Degenerative disease, Human, Science and Technology of Advanced Materials, Animal, Hydrogel, Thermoregulation, Cancer, Kansai University, Temperature, Science, Myocardial infarction, Heart, Time, Blood, Gel, Medical imaging

The hydrogel acts as a scaffold that holds the stem cells in place at the site of injection and keeps them alive for longer.

Key Points: 
  • The hydrogel acts as a scaffold that holds the stem cells in place at the site of injection and keeps them alive for longer.
  • Firstly, they developed hydrogel formulas that can hold stem cells in place for longer periods of time at the site of tissue damage.
  • The team added adipose-derived stem cells to the hydrogel and observed, both in petri dishes and inside mouse heart tissue, how long the cells lived and what kinds of genes and substances were produced by the cells.
  • They also plan to investigate using their injectable hydrogel to deliver immune cells to treat cancer or in vaccines to protect against viral infections.

Kane Biotech Expands its Wound Care and Surgical Portfolio with a coactiv+TM Antimicrobial Hydrogel

Retrieved on: 
Thursday, July 22, 2021
Gels, Colloidal chemistry, Hydrogel, Water chemistry, Natural sciences, Wound, Clinical medicine, Health sciences

WINNIPEG, Manitoba, July 22, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces plans to expand its wound care and surgical portfolio with an antimicrobial hydrogel based on its best-in-class coactiv+ technology.

Key Points: 
  • WINNIPEG, Manitoba, July 22, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces plans to expand its wound care and surgical portfolio with an antimicrobial hydrogel based on its best-in-class coactiv+ technology.
  • Use of the coactiv+TM technology in wound care products will complement the companys disruptive DispersinB wound care product development efforts whilst enabling the pursuit of the simpler 510(k) regulatory route and potentially quicker market access.
  • Kane estimates the US market for wound care hydrogels to be approximately US$200M.
  • We are committed to getting our coactiv+TM technology in the hands of wound care professionals and their patients as quickly as possible.

Terasaki Institute for Biomedical Innovation and Tetratherix™ Form Collaboration

Retrieved on: 
Tuesday, July 20, 2021
Physical sciences, Natural sciences, Biomaterials, Chemistry, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Biocompatibility, Bio-ink, Draft:Terasaki Institute for Biomedical Innovation

LOS ANGELES, July 20, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with Tetratherix, a company which produces Tetramatrix, a synthetic injectable hydrogel currently being clinically tested in a variety of biomedical applications.

Key Points: 
  • LOS ANGELES, July 20, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with Tetratherix, a company which produces Tetramatrix, a synthetic injectable hydrogel currently being clinically tested in a variety of biomedical applications.
  • The unique and advantageous features of Tetramatrix offers the potential for further development into biocompatible, adhesive bioinks for deep tissue applications.
  • "This project will allow us to conduct world-class research in collaboration with TIBI to further expand our product pipeline in key therapeutic areas," said Ali Fathi, Tetratherix Founder and Director.
  • It is the hope that by optimizing the Tetramatrix bioinks, the TIBI researchers can help to translate them into viable biomedical applications.

Global Advanced Medical Dressings Market (2020 to 2025) - Featuring 3M, Cardinal Health and Coloplast Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 30, 2021
General Health, Other Health, Health, Pharmaceutical, Medical Supplies, Chemistry, Branches of biology, Physical sciences, Dressing, Hydrogel, Chitosan, Hyaluronic acid, Collagen, Biomaterial

Interactive dressings include foam, film, hydrogels, and hydrocolloids.

Key Points: 
  • Interactive dressings include foam, film, hydrogels, and hydrocolloids.
  • These contrast with traditional dressings that provide cover over the wound, e.g., gauze and tulle dressings.
  • Bioactive dressings are produced from biomaterials that play an important role in the healing process.
  • These dressings are known for their biocompatibility, biodegradability and nontoxic nature and are derived generally from natural tissues or artificial sources such as collagen, hyaluronic acid, chitosan, and elastin.

Sphere Fluidics and ClexBio introduce CYTRIX Microfluidic Hydrogel Kit

Retrieved on: 
Monday, June 7, 2021
Biotechnology, Genetics, Health, Stem cells, Natural sciences, Branches of biology, Biology, Biotechnology, Cell culture, Cell biology, Colloidal chemistry, Microfluidics, Nanotechnology, Hydrogel, Tissue engineering, Sphere Fluidics

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.

Key Points: 
  • Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.
  • The kit combines ClexBios novel CYTRIX Hydrogel with Sphere Fluidics specially designed Pico-Gen double aqueous biochip to allow the plug-and-play generation of defined, reproducible and tailorable hydrogel microstructures for 3D cell culture, organoids, single-cell analysis, and many other applications.
  • The CYTRIX Hydrogel overcomes the challenges of existing microfluidic hydrogel formation techniques, such as clogging, finicky temperature control or time-critical mixing procedures.
  • For further information about the CYTRIX Microfluidic Hydrogel Kit, please visit: https://spherefluidics.com/microfluidic-hydrogel/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005345/en/